Information  X 
Enter a valid email address

OptiBiotix Health (OPTI)

  Print      Mail a friend

Wednesday 03 July, 2019

OptiBiotix Health

License agreement for LPLDL® in Japan

RNS Number : 2614E
OptiBiotix Health PLC
03 July 2019

OptiBiotix Health plc

("OptiBiotix" or the "Company")


License agreement for LPLDL® in Japan


OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a non-exclusive license agreement with Tenshindo, Co. Ltd. ("Tenshindo") for the use of Lactobacillus plantarum LPLDL® ("LPLDL®") in cardiovascular food supplements in Japan.


Tenshindo is a manufacturer of functional food and cosmetics products founded in Japan in 1986. LPLDL® will be the active ingredient in a novel cardiovascular health product that Tenshindo will add to its current portfolio of over 50 products. Tenshindo and ProBiotix will work together to obtain an authorised cardiovascular health claim for LPLDL® from the Japanese authorities, based on the existing clinical and market evidence on the strain.


This is the first end product application deal in Japan emerging from ProBiotix's agreement with the local distributor EIWA Trading Corporation in February 2019 (RNS: 11 February 2019) to distribute LPLDL® in the country, and part of the Company's strategy to include LPLDL® in a wide range of cardiovascular health supplements, and in food, dairy, and beverage products across the world. EIWA and ProBiotix are working together to replicate this model with different partners and different applications in the Japanese market.


Dr. Luis Gosalbez, Business Development Director of OptiBiotix, commented: "We are pleased to announce this deal with Tenshindo, which will mean our first LPLDL® finished product placement on the Japanese market.

Obtaining an authorised cardiovascular health claim for LPLDL® from Japanese authorities will not only be highly advantageous from the commercial point of view, but also an important endorsement for ProBiotix's science. Tenshindo, with over 30 years of experience in this market, are an excellent commercial and regulatory partner to make the most of this opportunity."



This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


For further information, please contact:


OptiBiotix Health plc

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880


finnCap (Broker)

Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)

Camille Gochez (Corporate Broking)


Tel: 020 7220 0500


goetzpartners securities Limited

Ulrich Kinzel  


Walbrook PR Ltd



Tel: 0203 859 7725

Anna Dunphy

Mob: 07876 741 001






About OptiBiotix - 


OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.


OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.


OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t